DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable.